Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1‐receptor agonist, in hypertensive patients.
Open Access
- 1 January 1988
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 25 (1) , 17-21
- https://doi.org/10.1111/j.1365-2125.1988.tb03276.x
Abstract
1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1‐receptor agonist, were studied in 10 patients with essential hypertension. 2 Reduction in blood pressure was linearly related to the log fenoldopam plasma concentration (r = 0.69) and the log fenoldopam infusion rate (r = 0.71). 3 The mean elimination half‐life (+/‐ s. e. mean) was 9.8 +/‐ 1.0 min. The total body clearance was 30.3 +/‐ 2.3 ml kg‐1 min‐1 and the volume of distribution was 582 +/‐ 62 ml kg‐1. 4 The rapid onset of action, short elimination half‐life, linear dose‐ response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required.This publication has 10 references indexed in Scilit:
- The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamicsClinical Pharmacology & Therapeutics, 1987
- The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.British Journal of Clinical Pharmacology, 1986
- Determination of fenoldopam (SK&F 82526) and its metabolites in human plasma and urine by high-performance liquid chromatography with electrochemical detectionJournal of Chromatography A, 1984
- Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.Journal of Clinical Investigation, 1984
- Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.Circulation, 1984
- PHARM—An interactive graphic program for individual and population pharmacokinetic parameter estimationComputers in Biology and Medicine, 1984
- A new oral renal vasodilator, fenoldopamClinical Pharmacology & Therapeutics, 1983
- CHARACTERIZATION OF THE PERIPHERAL AND CENTRAL EFFECTS OF SK-AND-F 82526, A NOVEL DOPAMINE RECEPTOR AGONIST1982